Crescent Biopharma reports news about its clinical-stage oncology pipeline, including CR-001, a PD-1 x VEGF bispecific antibody, and antibody-drug conjugate programs such as CR-002 and CR-003. Company updates commonly cover clinical trial activity in solid tumors, pipeline combinations, collaboration activity, financial results, and business highlights.
Recurring corporate announcements also include investor conference presentations and equity inducement awards under the company’s employment inducement incentive plan. These updates reflect Crescent’s status as a Nasdaq-listed biotechnology issuer focused on cancer therapeutics.
Crescent Biopharma (CBIO) reported third-quarter 2026 financial results and completed dose escalation in its Phase 1/2 ASCEND cancer trial. Quarterly net loss widened to $37.7 million from $24.6 million a year earlier, while ordinary-share loss narrowed to $0.90 from $1.27. Cash and cash equivalents were $289.4 million at September 30, including July offering proceeds; Crescent expects funding into the second half of 2028.
More than 125 patients have received CR-001 in ASCEND. Crescent expects initial monotherapy results in Q1 2027 and chemotherapy-combination data in Q2/Q3 2027. Partner Kelun-Biotech expects initial CR-001/sac-TMT lung cancer data in Q2/Q3 2027. The first patient received CR-002 in APOLLO, with initial results expected in the second half of 2027. CR-003 proof-of-concept data from its China trial are expected in Q1 2027.
Crescent Biopharma (CBIO) announced inducement stock options covering 11,775 ordinary shares for one non-executive employee who accepted employment with the company. The Compensation Committee approved the award on November 2, 2026, under its amended 2025 Employment Inducement Incentive Award Plan.
The options have a $12.91 exercise price, matching the November 2 Nasdaq closing share price, and a 10-year term. One-fourth vests on the first anniversary of the employee’s start date, followed by one-forty-eighth monthly thereafter, subject to continuous service through each vesting date.
Crescent Biopharma (CBIO) management is scheduled to present at investor conferences on November 9, 10 and 18, 2026.
Fireside chats are scheduled at Guggenheim in Boston at 8:30 a.m. ET, Stifel in New York at 1:20 p.m. ET, and Jefferies in London at 3:00 p.m. GMT/10:00 a.m. ET, respectively. Each presentation will be webcast through the company’s investor website, with replays available for 90 days.
Crescent Biopharma (CBIO) has begun enrolling patients in chemotherapy combination cohorts of its global Phase 1/2 ASCEND cancer trial of CR-001. Dose escalation is complete, with more than 125 patients dosed. Crescent plans initial monotherapy results in Q1 2027, including preliminary tumor response in up to 12 first-line non-small cell lung cancer patients, and chemotherapy combination results in mid-2027.
Kelun-Biotech is advancing CR-001 combinations with sac-TMT, an antibody linked to a cancer drug, with initial data expected in mid-2027. Crescent targets CR-002 APOLLO dosing this quarter following FDA clearance to begin clinical testing; initial data are expected in the second half of 2027. CR-003 data from China are expected in Q1 2027. Crescent anticipates more than 2,000 patients dosed across its portfolio by mid-2027 and plans its first CR-001 Phase 3 trial in early 2028, pending results and further regulatory interactions.
Crescent Biopharma (CBIO) approved inducement options covering 81,525 ordinary shares for six non-executive employees on October 5, 2026.
The independent Compensation Committee approved the awards under the amended 2025 Employment Inducement Incentive Award Plan. The options have a 10-year term and a $13.94 exercise price, matching the Nasdaq closing share price on the approval date. The awards were material to each employee’s acceptance of employment. One-fourth of each award becomes exercisable on the first anniversary of the employee’s start date, followed by one-forty-eighth monthly, subject to continuous service through each vesting date.
Crescent Biopharma (Nasdaq: CBIO) received FDA clearance of its Investigational New Drug application for CR-002 to treat advanced solid tumors. CR-002 is an antibody-drug conjugate, an antibody linked to a drug, targeting PD-L1 and carrying a topoisomerase inhibitor.
Crescent plans to initiate the Phase 1/2 APOLLO global trial in the fourth quarter of 2026, enrolling patients in the United States, Europe and Asia Pacific. Tumor types include non-small cell lung cancer, head and neck squamous cell carcinoma, and gastrointestinal and gynecological tumors. Dose escalation and tumor-specific backfill cohorts are expected to enroll approximately 200 participants, with additional participants possible in expansion cohorts. Crescent expects initial data in the second half of 2027, covering safety, pharmacokinetics—how the body processes the drug—and preliminary antitumor activity across multiple tumor types.
Crescent Biopharma (CBIO) approved inducement options covering 31,200 ordinary shares for two non-executive employees on September 24, 2026.
The options have a 10-year term and a $14.24 exercise price, equal to the closing price of Crescent’s ordinary shares on Nasdaq on September 24. One-fourth of each employee’s options vest on the first anniversary of their start date, followed by one-forty-eighth monthly, subject to continued service through each vesting date. The awards were material to the employees’ acceptance of employment and are governed by Crescent’s amended 2025 Employment Inducement Incentive Award Plan.
Crescent Biopharma (CBIO) granted stock options to purchase a total of 58,650 ordinary shares to two non-executive employees as equity inducement awards under its 2025 Employment Inducement Incentive Award Plan, as amended. The independent Compensation Committee approved the options on September 8, 2026 in reliance on Nasdaq Listing Rule 5635(c)(4).
The options have a 10-year term and an exercise price of $20.46, equal to the September 8, 2026 closing price of Crescent’s ordinary shares on Nasdaq. For each employee, one-fourth of the shares subject to the option vest on the first anniversary of the employee’s start date, with the remaining three-fourths vesting in equal monthly installments over the following three years, subject to continuous service and the terms of the Inducement Plan and related option agreements.
Crescent Biopharma (CBIO)/b) will present at two September 2026 investor conferences via fireside chats in New York.Management is scheduled for the 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026 at 1:35 p.m. ET and the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 5:35 p.m. ET. Live webcasts and 90-day replays will be available in the Investors section of the company website.
Crescent Biopharma (Nasdaq: CBIO) announced that the independent Compensation Committee of its Board approved equity inducement awards for one non-executive employee under the 2025 Employment Inducement Incentive Award Plan. The grant consists of options to purchase an aggregate of 19,425 ordinary shares, approved on July 31, 2026, and intended to be material to the employee’s acceptance of employment in line with Nasdaq Listing Rule 5635(c)(4).
The stock options have a 10-year term and an exercise price of $14.47, equal to Crescent’s July 31, 2026 Nasdaq closing price. Vesting occurs as to one-fourth of the shares on the first anniversary of the employee’s start date, with the remaining shares vesting in equal monthly installments over the following three years, subject to continuous service and the terms of the Inducement Plan and the applicable option agreement.